Rabbit antithymocyte globulin dose and early subclinical and clinical rejections in kidney transplantation

Antithymocyte globulin (ATG) is a commonly used induction agent in kidney transplant recipients. However, the optimal dosing has not been well defined. Our protocol aims for a 5–6 mg/kg cumulative dose. It is unclear if a dose lower than 5 mg/kg is associated with more rejection.

[1]  P. Nickerson,et al.  The negative impact of T cell–mediated rejection on renal allograft survival in the modern era , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[2]  H. Tedesco-Silva,et al.  The influence of the antithymocyte globulin dose on clinical outcomes of patients undergoing kidney retransplantation , 2021, PloS one.

[3]  A. Israni,et al.  OPTN/SRTR 2019 Annual Data Report: Kidney , 2021, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  A. Rajab,et al.  Antithymocyte induction dosing and incidence of opportunistic viral infections using steroid‐free maintenance immunosuppression , 2020, Clinical transplantation.

[5]  J. Friedewald,et al.  Kidney Graft Surveillance Biopsy Utilization and Trends: Results From a Survey of High-Volume Transplant Centers. , 2020, Transplantation proceedings.

[6]  P. Randhawa,et al.  Early subclinical tubulitis and interstitial inflammation in kidney transplantation have adverse clinical implications. , 2020, Kidney international.

[7]  W. Park,et al.  Effectiveness of Antithymocyte Globulin Induction Dosing Regimens in Kidney Transplantation Patients: A Network Meta-analysis. , 2019, Transplantation proceedings.

[8]  Jan U. Becker,et al.  A 2018 Reference Guide to the Banff Classification of Renal Allograft Pathology , 2018, Transplantation.

[9]  A. Cherukuri,et al.  Short‐term adverse effects of early subclinical allograft inflammation in kidney transplant recipients with a rapid steroid withdrawal protocol , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  R. Mannon,et al.  Subclinical inflammation phenotypes and long‐term outcomes after pediatric kidney transplantation , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  H. Noh,et al.  Thymoglobulin Versus Basiliximab Induction Therapy in Low-Risk Kidney Transplant Recipients: A Single-Center Experience. , 2018, Transplantation proceedings.

[12]  Namita Singh,et al.  Tailored Rabbit Antithymocyte Globulin Induction Dosing for Kidney Transplantation , 2018, Transplantation direct.

[13]  M. Nafar,et al.  The appropriate dose of thymoglobulin induction therapy in kidney transplantation , 2017, Clinical transplantation.

[14]  S. Hariharan,et al.  Kidney allograft surveillance biopsy practices across US transplant centers: A UNOS survey , 2017, Clinical transplantation.

[15]  A. Farney,et al.  A Double‐Blind, Double‐Dummy, Flexible‐Design Randomized Multicenter Trial: Early Safety of Single‐ Versus Divided‐Dose Rabbit Anti‐Thymocyte Globulin Induction in Renal Transplantation , 2016, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[16]  Jeong M. Park,et al.  Evaluation of a Weight‐based Rabbit Anti‐thymocyte Globulin Induction Dosing Regimen for Kidney Transplant Recipients , 2015, Pharmacotherapy.

[17]  Scott R. Johnson,et al.  Renal Transplantation in the Setting of Early Steroid Withdrawal: A Comparison of Rabbit Antithymocyte Globulin Induction Dosing in Two Eras , 2013, American Journal of Nephrology.

[18]  W. Weimar,et al.  The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. , 2012, Transplant immunology.

[19]  Spencer T. Martin,et al.  Induction Treatment with Rabbit Antithymocyte Globulin versus Basiliximab in Renal Transplant Recipients with Planned Early Steroid Withdrawal , 2011, Pharmacotherapy.

[20]  S. Mulgaonkar,et al.  A prospective, randomized, multicenter study evaluating early corticosteroid withdrawal with Thymoglobulin® in living‐donor kidney transplantation , 2010, Clinical transplantation.

[21]  A. Langnas,et al.  Randomized Trial of Single-Dose Versus Divided-Dose Rabbit Anti-Thymocyte Globulin Induction in Renal Transplantation: An Interim Report , 2008, Transplantation.

[22]  D. Brennan,et al.  Rabbit antithymocyte globulin versus basiliximab in renal transplantation. , 2006, The New England journal of medicine.

[23]  W. Winkelmayer,et al.  Comparison of two dosages of thymoglobulin used as a short‐course for induction in kidney transplantation , 2006, Transplant international : official journal of the European Society for Organ Transplantation.

[24]  T. Howard,et al.  Short course induction immunosuppression with thymoglobulin for renal transplant recipients. , 2002, Transplantation.

[25]  P. Nickerson,et al.  Beneficial effects of treatment of early subclinical rejection: a randomized study. , 1998, Journal of the American Society of Nephrology : JASN.

[26]  Robert Kerchner,et al.  Interim Report , 1996 .